Abiomed (ABMD) Halted Ahead of FDA Meeting on Blood Pumps
- S&P 500 ends flat; Fed sees risks but unlikely to reverse course
- Twitter (TWTR) Tops Q4 EPS by 4c; MAUs Miss
- Tesla (TSLA) Posts Q4 Loss of 87c/Share; Delivered 17,478 Vehicles, Above Expectations
- Mylan (MYL) Enters Agreement to Acquire Meda in ~$9.9B Deal
- After-Hours Stock Movers 02/10: (HUBS) (EXPE) (TSLA) Higher; (PPC) (MYL) (ZNGA) Lower (more...)
Abiomed, Inc. (NASDAQ: ABMD) halted ahead of FDA advisory committee meeting over nonroller-type cardiopulmonary bypass blood pumps.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abiomed (ABMD) Appoints Two New Board Members
- Conifer Holdings, Inc. (CNFR) halted with news pending
- Lift of Partial Clinical Hold on Heat Biologics' (HTBX) HS-410 Much Earlier than Expected; Noble Reaffirms at 'Buy'
Create E-mail Alert Related CategoriesFDA, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!